Document is current
Any future updates will be listed below
-
Authors
O’Logbon, Jessica https://orcid.org/0000-0003-1216-9703
Tarantola, Ludovica https://orcid.org/0000-0001-7922-1997
Williams, Norman R. https://orcid.org/0000-0001-6496-312X
Mehta, Shreeya
Ahmed, Aamir https://orcid.org/0000-0001-7405-5336
Davies, Elizabeth A. https://orcid.org/0000-0003-2325-0849
- License Information
-
More Information
Article History
Received: 10 May 2025
Accepted: 25 June 2025
First Online: 12 July 2025
Declarations
:
: A.A. is the CEO of Oncolodyne, a pre-clinical and clinical stage drug discovery company focused on reprofiling drugs for cancer therapy. This work received no funding from Oncolodyne or any other source, and the company had no involvement in the conception, design, analysis, or writing of this systematic review. All other authors declare no competing interests.
